PriceTargets.com logo

Benitec Biopharma - BNTC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.71
  • Forecasted Upside: 80.00%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 2 Strong Buy Ratings
$13.73 As of 04/23/2025 03:03 PM ET
▼ -0.06 (-0.44%)

This chart shows the closing price for BNTC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
FebMarApr$13.78Closing price on 04/22/25:
Get New Benitec Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BNTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BNTC

Analyst Price Target is $24.71
▲ +80.00% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Benitec Biopharma in the last 3 months. The average price target is $24.71, with a high forecast of $35.00 and a low forecast of $13.00. The average price target represents a 80.00% upside from the last price of $13.73.

This chart shows the closing price for BNTC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
4/247/2410/241/254/255/26$4.41$12$20$27$35Closing price on 04/22/25: $13.78High$35.00Average$24.71Low$13.00




Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in Benitec Biopharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2024
  • 2 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2025
  • 2 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 2 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2025

Latest Recommendations

  • 2 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/10/2025JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$18.00 ➝ $20.00
3/24/2025HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
2/21/2025HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
12/16/2024HC WainwrightInitiated CoverageBuy$28.00
12/13/2024Robert W. BairdInitiated CoverageOutperform$30.00
12/12/2024Baird R WUpgradeStrong-Buy
12/3/2024GuggenheimReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
10/18/2024Piper SandlerReiterated RatingOverweight ➝ Overweight
10/16/2024OppenheimerInitiated CoverageOutperform$35.00
10/14/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $18.00
9/30/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$16.00 ➝ $16.00
9/12/2024GuggenheimInitiated CoverageBuy$17.00
7/22/2024Leerink PartnrsUpgradeStrong-Buy
7/22/2024Leerink PartnersInitiated CoverageOutperform$13.00
6/13/2024Piper SandlerInitiated CoverageOverweight$30.00
4/22/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $16.00
2/15/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $10.00
1/24/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$6.00 ➝ $8.00
9/26/2023JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$6.50
10/18/2022JMP SecuritiesInitiated CoverageMarket Outperform$68.00
9/23/2022HC WainwrightLower TargetBuy$170.00 ➝ $68.00
2/17/2022HC WainwrightInitiated CoverageBuy$170.00
10/5/2020LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
(Data available from 4/23/2020 forward)

News Sentiment Rating

0.93 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/25/2024
  • 8 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/25/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/24/2024
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/24/2024
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/23/2025
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/22/2025
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2025
  • 10 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2025

Current Sentiment

  • 10 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Benitec Biopharma logo
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Read More

Today's Range

Now: $13.73
Low: $13.55
High: $13.99

50 Day Range

MA: $12.95
Low: $10.53
High: $16.79

52 Week Range

Now: $13.73
Low: $5.74
High: $16.90

Volume

20,723 shs

Average Volume

41,342 shs

Market Capitalization

$321.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Benitec Biopharma?

The following Wall Street research analysts have issued stock ratings on Benitec Biopharma in the last year: Baird R W, Guggenheim, HC Wainwright, JMP Securities, Leerink Partners, Leerink Partnrs, Oppenheimer Holdings Inc., Piper Sandler, and Robert W. Baird.
View the latest analyst ratings for BNTC.

What is the current price target for Benitec Biopharma?

0 Wall Street analysts have set twelve-month price targets for Benitec Biopharma in the last year. Their average twelve-month price target is $24.71, suggesting a possible upside of 80.0%. Oppenheimer Holdings Inc. has the highest price target set, predicting BNTC will reach $35.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $13.00 for Benitec Biopharma in the next year.
View the latest price targets for BNTC.

What is the current consensus analyst rating for Benitec Biopharma?

Benitec Biopharma currently has 7 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BNTC will outperform the market and that investors should add to their positions of Benitec Biopharma.
View the latest ratings for BNTC.

What other companies compete with Benitec Biopharma?

Other companies that are similar to Benitec Biopharma include Evotec, Indivior, Ocular Therapeutix, Calliditas Therapeutics AB (publ) and Amphastar Pharmaceuticals. Learn More about companies similar to Benitec Biopharma.

How do I contact Benitec Biopharma's investor relations team?

Benitec Biopharma's physical mailing address is Level 14 114 William St, Melbourne C3, 3000. The biotechnology company's listed phone number is 510-780-0819 and its investor relations email address is jmorakis@mgroupsc.com. The official website for Benitec Biopharma is www.benitec.com. Learn More about contacing Benitec Biopharma investor relations.





Receive Benitec Biopharma News & Ratings Daily
Sign up to receive the latest news and ratings for Benitec Biopharma and its competitors with PriceTargets.com’s free daily newsletter.